or Try an Advanced Search...

    Technical Analysis for ALDX - Aldeyra Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 4.21 -1.41% -0.06
    ALDX closed down 1.41 percent on Friday, November 15, 2024, on 1.4 times normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ALDX trend table...
    Date Alert Name Type % Chg
    200 DMA Resistance Bearish 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Below Lower BB Weakness 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Down 5 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Fell Below 200 DMA Bearish -1.41%
    Lower Bollinger Band Walk Weakness -1.41%
    Older End-of-Day Signals for ALDX ...

       Recent Intraday Alerts

    Alert Time
    Down 3% 1 day ago
    Fell Below Previous Day's Low 1 day ago
    60 Minute Opening Range Breakdown 1 day ago
    Down 2 % 1 day ago
    Rose Above Lower Bollinger Band 1 day ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ALDX Chart by TradingView
    Basic chart:

    Profile

    Aldeyra Therapeutics, Inc. (Aldeyra) is a biotechnology company. The Company is focused primarily on the development of products to treat immune-mediated, inflammatory, orphan, and other diseases that are thought to be related to a naturally occurring toxic chemical species known as free aldehydes. The Company is developing NS2. NS2 is a product candidate that is designed to trap and allow for disposal of free aldehydes, for the treatment of diseases, which include Sjogren-Larsson Syndrome (SLS), discoid lupus, acute anterior uveitis and ocular rosacea with meibomian gland dysfunction. Aldeyra is also developing aldehyde traps distinct from NS2. As of April 7, 2014, it had evaluated NS2 in a Phase I clinical trial in 48 volunteers.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Disease Organ Systems Autoimmune Disease Rare Diseases Dysfunction Lupus Syndromes Inflammatory Uveitis Rosacea Systemic Lupus Erythematosus Discoid Lupus Meibomian Gland Ns2

    Is ALDX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Sep 5 Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
    Sep 4 High Growth Tech Stocks To Watch In The United States
    Aug 30 Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory
    Aug 28 Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership
    Aug 9 Aldeyra’s Phase III clinical trial of Reproxalap meets primary endpoint
    Aug 8 Aldeyra climbs after late-stage success for dry eye disease therapy
    Aug 8 Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
    Aug 7 Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap
    Jul 31 Owning 36% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX),
    Jun 20 Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
    See more ALDX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.5476
    52 Week Low 2.43
    Average Volume 446,073
    200-Day Moving Average 4.31
    50-Day Moving Average 5.45
    20-Day Moving Average 5.22
    10-Day Moving Average 4.98
    Average True Range 0.34
    RSI (14) 29.08
    ADX 19.81
    +DI 15.96
    -DI 33.31
    Chandelier Exit (Long, 3 ATRs) 5.14
    Chandelier Exit (Short, 3 ATRs) 5.12
    Upper Bollinger Bands 6.11
    Lower Bollinger Band 4.34
    Percent B (%b) -0.07
    BandWidth 33.88
    MACD Line -0.25
    MACD Signal Line -0.12
    MACD Histogram -0.1318
    Fundamentals Value
    Market Cap 247.64 Million
    Num Shares 58.8 Million
    EPS -0.78
    Price-to-Earnings (P/E) Ratio -5.40
    Price-to-Sales 0.00
    Price-to-Book 1.58
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.57
    Resistance 3 (R3) 4.57 4.45 4.51
    Resistance 2 (R2) 4.45 4.36 4.45 4.49
    Resistance 1 (R1) 4.33 4.30 4.27 4.33 4.47
    Pivot Point 4.21 4.21 4.18 4.21 4.21
    Support 1 (S1) 4.09 4.12 4.03 4.09 3.95
    Support 2 (S2) 3.97 4.06 3.97 3.93
    Support 3 (S3) 3.85 3.97 3.91
    Support 4 (S4) 3.85